The Ubiquitin Proteasome System in Neurodegenerative Diseases: Sometimes the Chicken, Sometimes the Egg sponse, and neurodegeneration. While inactivation of a major enzyme, such as E1, is obviously lethal, mutations in enzymes or in recognition motifs in substrates that do not affect vital pathways or that affect the involved process only partially result in a broad array of pheno- , the pathogenetic linkage beThe ubiquitin-proteasome system targets numerous cellular proteins for degradation. In addition, modificatween the aberration in the system and the resulting disease is direct (the egg, according to one view). In tions by ubiquitin-like proteins as well as proteins containing ubiquitin-interacting and -associated motifs many other cases, however, it appears that the aggregated, disease-specific proteins that characterize many modulate many others. This tightly controlled process involves multiple specific and general enzymes of the of these disorders inhibit the activity of the UPS. Here, inhibition of the system may play a secondary role in system as well as many modifying and ancillary proteins. Thus, it is not surprising that ubiquitin-mediated the pathogenetic process (the chicken). In addition to Parkinson's disease, this review discusses Alzheimer's degradation/processing/modification regulates a broad array of basic cellular processes. Moreover, aberradisease, Prion diseases, familial amyotrophic lateral sclerosis (ALS) with mutations in the SOD1 gene, and tions in the system have been implicated, either as a primary cause or secondary consequence, in the polyglutamine expansion disorders. In each case, the potential role of the UPS is critically discussed, with an pathogenesis of both inherited and acquired neurodegenerative diseases. Recent findings indicate that the emphasis given to whether the observed changes are primary or whether they are secondary phenomena resystem is involved in the pathogenesis of Parkinson's, Alzheimer's, Huntington's, and Prion diseases as well sulting from another underlying cause. as amyotrophic lateral sclerosis. This raises hopes for a better understanding of the pathogenetic mechaThe Ubiquitin-Proteasome Pathway nisms involved in these diseases and for the developDegradation of a protein via the ubiquitin-proteasome ment of novel, mechanism-based therapeutic modalpathway involves two discrete and successive steps: ities.
gated ubiquitin molecule, a polyubiquitin chain is synthesized. The degradation signal that is recognized by the 26S proteasome complex is made of a Lys48 polyubiquitin chain. Conjugation to other Lys residues, Lys63 for example, serves nonproteolytic functions of the system, such as activation of transcription.
It appears that E3s play a key role in the ubiquitinmediated proteolytic cascade since they serve as the specific substrate recognition factors of the system. Approximately 1000 different E3s have been identified in the human genome, based on specific, commonly shared structural motifs, such as the RING finger. In some cases, proteins are modified by a single ubiquitin moiety. In many of these cases, the modification leads to targeting of the tagged substrate for degradation in the lysosome/vacuole. It should be noted that modification by a single ubiquitin moiety is catalyzed via an identical mechanism and set of enzymes to those that catalyze polyubiquitination. In some other cases, the first ubiquitin moiety is conjugated to the substrate by one E3, while chain elongation is catalyzed by a different ligase, often termed E4.
Degradation of polyubiquitinated substrates is carried out by a large protease complex, the 26S proteasome that does not generally recognize nonmodified substrates. In one established and exceptional case, however, that of the polyamine synthesizing enzyme ornithine decarboxylase (ODC), the proteasome recognizes have a 19S subcomplex on one side and a different complex, e.g., PA28, on the other. This polar organizaubiquitin is transferred once again from the E2 enzyme tion can secure unidirectionality in the flow of subto an active site Cys residue on the E3 to generate strates, and also, according to certain studies, generaa third high-energy thiol ester intermediate, ubiquitintion of preferred peptide products such as antigenic S‫ف‬E3, prior to its transfer to the ligase bound substrate.
epitopes that are trimmed properly to fit recognition by On the other hand, RING finger-containing E3s catalyze, the MHC class I molecules and the cytotoxic T cell. most probably, direct transfer of the activated ubiquitin One important function of the 19S RP is to recognize moiety from E2 to the E3 bound substrate. Members of ubiquitinated proteins and other potential substrates of other families of E3s, such as the U-Box-or PHD domainthe proteasome. Two ubiquitin binding subunits of the containing ligases, act most probably in a similar manner 19S RP have been identified, Rpn10 (S5a in mammalian to that of the RING finger ligases. E3s catalyze the last cells) and Rpt5 (S6Ј); however, their essential role and step in the conjugation process: covalent attachment mode of action have not been discerned. A second funcof ubiquitin to the substrate. The first ubiquitin moiety tion of the 19S RP is to open an orifice in the ␣ ring is generally transferred to an ⑀-NH 2 group of an internal that will allow entry of the substrate into the proteolytic Lys residue in the substrate to generate a covalent isochamber. Also, since a folded protein would not be able peptide bond. In some cases, however, it is conjugated to fit through the narrow proteasomal channel, it is aslinearly to the free NH 2 group at the N-terminal residue. sumed that the 19S particle unfolds substrates and inBy successively adding additional activated ubiquitin serts them into the 20S CP. Both the channel opening function and the unfolding of the substrate require metamoieties to internal Lys residues on the previously conju-bolic energy, and indeed, the 19S RP contains six differsors, and transcriptional activators and their inhibitors. Cell surface receptors and ER proteins are also targeted ent ATPase subunits. Following degradation of the substrate, short peptides are released along with free and by the system. Finally, mutated and denatured/misfolded proteins are recognized specifically and are rereusable ubiquitin. The peptides are further degraded by cytosolic amino-and carboxypeptidases, although moved efficiently. In this capacity, the UPS plays a key role in the cellular quality control and defense mechaa small fraction of them are transported across the endoplasmic reticulum (ER) membrane, bind to MHC class I nisms. The UPS can be regulated at the level of ubiquitination molecules, and are presented to cytoxic T cells. Proteasomal degradation does not always generate peptides.
or at the level of proteasome activity. Since conjugation and proteasomal degradation are required for numerous In some cases, the proteasome processes the ubiquitinated substrate precisely, releasing a truncated prodcellular functions, regulation must be delicately and specifically tuned. In a few cases, general rather than speuct. In the case of the NF-B transcriptional regulator, active subunits are generated from longer inactive precific components of the system can be modulated by physiological signals. For example, upregulation of the cursors.
In spite of the major progress that has been made in pathway is observed during massive degradation of skeletal muscle proteins that occurs under normal fastelucidating the mode of action of the UPS, major problems have remained unsolved. For example, how does ing but also under pathological conditions such as cancer-induced cachexia, severe sepsis, metabolic acidothe system achieve its high specificity and selectivity? Why are certain proteins extremely stable in the cell, sis, or following denervation. In most cases, however, regulation is specific, and the target substrates are recwhile others are extremely short-lived? Why are certain proteins degraded only at a particular time point during ognized by specific ligases that bind to defined motifs. The targeting motif can be a single amino acid residue the cell cycle or only following specific extracellular stimuli, yet are stable under most other conditions? It (e.g., the N-terminal residue), a sequence (the Destruction box in cyclins), or a domain (a hydrophobic patch, appears that specificity of the ubiquitin system is determined by two distinct and unrelated groups of proteins:
for example) that is not normally exposed. In other cases, the motif is generated posttranslationally, e.g., (1) E3s and (2) While the mutation did not lead to complete inactivation It has not been demonstrated, however, to modify actin. Yet, it is possible that the ligase regulates actin activity of the enzyme, the hydrolase was clearly less active compared to its wild-type counterpart. The simple exby ubiquitinating an actin-associated protein, which in turn affects the function of actin and thereby influences planation is that the mutation leads to a shortage in free ubiquitin that should have been recycled from conjuthe movement of synaptic vesicles. Detailed study of Drosophila parkin null mutant revealed reduced life gates, which results in general impairment of the function of the UPS. This impairment leads, in turn, to accuspan, locomotor disorders (in flight and climbing), and selective male sterility (Greene et al., 2003). Only a submulation of certain proteins that may be toxic to neurons. Interestingly, inactivation of UCH-L1 in mice set of dopaminergic neurons was affected. The disorders in locomotion were caused initially by disruption does not lead to dopaminergic neuronal death but to Gracile Axonal Dystrophy (GAD) syndrome. This is a in muscle integrity that later evolved into cell death. Sterility was caused by a late defect in spermatogenesis, recessive autosomal disease that results in sensory ataxia at an early stage, followed by motor ataxia at a occurring at the individualization stage. Importantly, the earliest defect observed in both muscles and spermalater stage (Saigoh et al., 1999). The GAD mice display axonal degeneration in the gracile tract of the spinal tids was mitochondrial dysfunction-displayed by swelling and disintegration of matrix and cristae. Thus, while cord and medulla oblongata but not cell death in the substantia nigra. The mutation in UCH-L1 that was found the parkin dysfunction syndromes in the fly and human appear to be distinct, they may share a similar basic linked to PD was identified as I93M. It should be noted that the mutation was not identified via gene linkage pathogenetic mechanism-aberration in mitochondrial function. studies but rather through a gene association study. Although the causative relationship between the mutaIn summary, recent findings regarding Parkin clearly point toward different direct etiological roles that this tion and the disease appears to be strong, it is nevertheless circumstantial at this stage. Since the mutation is enzyme may have in the pathogenesis of AR-JP. As noted, however, it is not clear whether the collective not 100% penetrant and since the GAD mice do not display a Parkinsonian syndrome-neither clinically nor accumulation of all of its substrates-the known and those left to be discovered-is toxic to the dopaminergic histopathologically-it is not clear whether loss of the ubiquitin hydrolytic activity underlies the entire patholcells or if there is one protein in particular that is toxic. It is also unclear why catecholaminergic neurons of the ogy observed in patients with the I93M mutation. Therefore, it was suggested that, in addition to the loss of the substantia nigra and locus ceruleus are selectively vulnerable to the loss of Parkin in AR-JP patients. It is ubiquitin hydrolytic activity, additional factor(s) may be involved in the pathogenetic process involved in PD. It possible that the high oxidative state associated with cathecolamine biosynthesis does not leave a large has been reported recently that while the monomeric form of UCH-L1 catalyzes deubiquitination, the dimers enough reserve of defense mechanisms to protect ). Due to the absence of the crucial C-terminal RGG, UBB ϩ1 cannot bind to target proteins. activity, although the levels of the ␣ and ␤ subunits of the proteasome were not changed. In contrast, the However, it can be ubiquitinated by wild-type ubiquitinproduced from correctly generated transcripts in the proteasomal activity was normal in the occipital lobe and cerebellum-regions involved in vision and motor same cell-that can bind to two specific lysine residues in UBB ϩ1 ( function. It is unlikely that an increased level of UBB ϩ1 2002). Finally, there is also evidence for a reduced activis a direct cause of AD because it occurs also in other ity of E1 and E2 enzymes in cerebral cortex samples neurodegenerative conditions. However, the recent refrom AD patients compared to age-matched controls ports showing that UBB ϩ1 can inhibit the proteasome (Lopez Salon et al., 2000) . Taken together, several lines suggest that it may contribute to disease pathogenesis. of evidence point to a reduced UPS function in AD and In summary, the evidence that the UPS plays a pivotal suggest that both A␤ and tau are important players in role in the pathogenesis of AD is compelling. The recent the game. One should be careful, however, in the interunraveling of the fascinating UBB ϩ1 story in AD suggests pretation of these data. It is not clear whether the inhibithat we may soon see many more completely novel tion of the proteasome is large enough to inflict damage pathogenetic mechanisms involved in neurodegenera-(see also above). Also, the observation of proteasometive diseases, and primary failure of the UPS could be dependent, yet ubiquitin-independent degradation of a key element in several of them. tau clearly requires further corroboration.
So is it the chicken or the egg? That is, does a reduction in the activity of the UPS lead to a greater tendency Prion Disease Prion diseases have brought the linkage between abnorof A␤ to accumulate and generate amyloid plaques, or do conformational changes in A␤ or tau cause proteamal protein conformation in its purest form and neurodegeneration to the center stage. This family of diseases some inhibition? One characteristic of AD is that it shows a higher prevalence with age. The ability to increase is considered to be caused by a protein component of the proteinaceous infectious (prion) particles, originally ubiquitin conjugation in response to stressors decreases in ageing tissue (Shang et al., 1997) . The proteaproposed to be the causative agent of these diseases by Stanley Pruisner (1982). As discussed later, recent some activity in the mammalian brain decreases with increasing age (Keller et al., 2002) What is the evidence that the UPS is functionally inhibproteins exceeding the capacity of the UPS to tag, target, and proteolytically degrade them. It has been specited or overwhelmed in cells expressing expanded polyglutamine proteins? At the outset, it is important to ulated that there may be a relative shortage of ubiquitin or related enzymes under these conditions. On the other stress that most studies in this area have been conducted in cultured cells where a truncated form of the hand, it can be argued that the presence of ubiquitin in the inclusion bodies indicates that the system does not mutant protein has been overexpressed. Both the level of expression and the length of the protein can have falter at the level of ubiquitination. However, the presence of ubiquitin in the aggregates does not guarantee significant impact on how it affects the UPS, and therefore some caution is warranted when extending the finda functional ubiquitination process, since the polyubiquitin chains may not be sufficiently long, for example, ings to the human diseases. An elegant demonstration that an expanded polyglutamine protein can cause functo target the misfolded protein molecules to the proteasome. Also, some of the ubiquitin in the inclusions may tional UPS inhibition was provided by Bence and colleagues ( mary cause of the pathology in polyglutamine diseases Somewhat contrary to these observations, Dantuma and is clearly defined by the mutation, the actual disease coworkers have found that only soluble polyglutamine manifestations may also reflect malfunction of the UPS. proteins are efficiently cleared by the proteasome from Therefore, a better understanding of how the UPS intercultured HeLa cells, and once they are captured in agacts with proteins expressing expanded polyglutamine gregates, they become virtually resistant to proteolysis tracts can lead to the development of therapeutic ap- (Verhoef et al., 2002) . Possibly, the type of cell model proaches. has some bearing on the results, and the issue of the activity of the UPS in cells expressing expanded polyConcluding Remarks glutamine proteins will require further investigation.
As described in this review, rare cases of slowly progCould the functional status of the UPS differ between ressing neurodegenerative diseases, notably PD and individuals due to genetic or epigenetic influences unre-AD, exhibit aberrations in the UPS that probably play a lated to the polyglutamine disease, and can this differprimary and direct role in the disease pathogenesis. ence play a role in governing the age of disease onset?
However, in many others, it appears that inhibition of The CAG repeat length in the mutant gene accounts for the UPS by the aggregated disease proteins may lead ‫%07ف‬ of the variance of age of onset for HD (Becher to a secondary neuronal damage. In a third large group et al., 1997), and individual differences in UPS activity of neurodegenerative diseases, the linkage between could influence the time it takes for mutant proteins to UPS impairment and disease pathogenesis is even more accumulate in the patient's brain. Interestingly, Li and remote and indirect, if it exists at all. This current state collaborators demonstrated recently that transgenic HD of knowledge makes it difficult to design mechanismmice do not display reduced proteasomal activity in the based therapeutic modalities based on the mode of brain but rather show a decline in enzyme activity with action of the UPS. In general, it appears that activation age (Zhou et al., 2003)-similar in both wild-type and of the UPS may have a beneficial effect in many of these transgenic mice of the same genetic background. Thus, disorders, yet, it appears that such an activation is hard the rate of age-related decline in UPS activity could to achieve. It is possible that once the mediators of define the efficacy with which the brain handles the general activation of the system, such as occurs in sepmutant proteins and thereby influence the age of onset sis, muscle atrophy, and cancer-induced cachexia, are of symptoms in an individual patient.
identified, their selective employment in neurodegenerThere are several possible consequences of the UPS ative disorders should be examined. Curiously, the only being inhibited in neurons as a result of expression of drug in the market that targets the UPS and that is expanded polyglutamine proteins. With our expanding used to treat multiple myeloma is a potent proteasome knowledge of the multiple roles of the UPS in a broad
inhibitor. From what we currently know, inhibition of the array of cellular functions, it will not be surprising to find proteasome will, most probably, aggravate the patholthat impairment of the UPS function can be devastating. ogy and consequently the symptoms of many of the However, it can be difficult to dissect out the effects of known neurodegenerative disorders. The effect of UPS inhibition from the direct effects of the aggregated "chemical/pharmacological chaperones" to dissolve the proteins per se and from the toxic effects of oligomers aggregated proteins cannot be predicted. While certain of mutant polyglutamine proteins. One immediate confindings indicate that the soluble proteins are neurosequence of inhibition of the UPS in cells expressing a toxic, alleviation of the inhibition of the UPS may have mutant polyglutamine protein is obviously impairment beneficial effects. Thus, such agents may have different in the clearing of misfolded proteins. Consequently, the effects in different diseases and therefore should be formation of aggregates may increase when the UPS examined in a systematic manner. Interestingly, such fails. Lunkes and colleagues demonstrated that trunagents are being examined in the treatment of cystic cated Huntingtin, which has undergone proteolytic fibrosis, where the mutated yet active ⌬F508 CFTR is cleavage in the cytoplasm, accumulates more rapidly if rapidly degraded via the ERAD pathway. The undethe proteasome is pharmacologically inhibited (Lunkes graded protein, however, is accumulated in aggreet al., 2002). This indicates that the truncated fragments somes. The hope is that some of the dissolved protein are normally processed via the UPS, and therefore the will evade ERAD and be expressed at the cell surface. disposal of fragments of mutant proteins will be imIt appears that a better mechanistic understanding of the paired. A study in cultured mouse neuroblastoma cells role that the UPS plays in neurodegeneration is required showed that N-terminal mutant Huntingtin inhibited the before specific and mechanism-based, rather than gen-20S proteasome catalytic activity, in turn causing imeral, modalities can be developed. paired proteasomal degradation of p53, subsequent loss of mitochondrial membrane potential, release of 
